medigraphic.com
ISSN 2992-8036 (Electronic)
ISSN 2306-4102 (Print)
Órgano Oficial del Colegio Mexicano de Ortopedia y Traumatología

2002, Number 2

<< Back Next >>

Acta Ortop Mex 2002; 16 (2)

Bone methastases produced by malignant breast tumors. Brief epidemiological report

Salazar PR, Axotla BVM, Parra GA

Language: Spanish
References: 29
Page: 51-55
PDF size: 397.62 Kb.


ABSTRACT

Objective. Present paper is an epidemiological trial intended to investigate in our hospital the behavior of breast cancer, that metastatizes to the skeleton, as it is one of the most common malignant tumors with bone metastasis in women, as a part of the tumor’s late natural course. Material and methods. A review of the records of 206 women who had breast cancer was developed from October 1998 through October 2000 in search for bone metastasis is reported. Results. Epidemiological data demonstrated that 45 out of the 206 patients (22%) had bone metastasis. More frequent were, costal bones in 34, lumbar spine in 22, skull in 18, thoracic spine and iliac crest in 15 each, and combined hip joint and proximal femur in 21. Conclusion. The number of bone metastatic tumors is significantly higher than primary bone tumors and the survival rate between diverse metastatic neoplasms is quite different. Survival in breast cancer is longer than in those cases produced by lung cancer.


REFERENCES

  1. Albertini JJ, Lyman GH, Cox C, et al. Lymphatic mapping and sentinel node biopsy in the patient with breast cancer. JAMA 1996; 276(22): 1818-22.

  2. American Society of Clinical Oncology: Statement of the American Society of Clinical Oncology: genetic testing for cancer susceptibility, adopted February 20, 1996. J Clin Oncol 1996; 14(5): 1730-6.

  3. Blichert-Toft M, Rose C, Andersen JA, et al. Danish randomized trial comparing breast conservation therapy with mastectomy: six years of life-table analysis. J Nat Can Inst Monog 1992; 11: 19-25.

  4. Degardin M, Bonneterre J, Hecquet B, et al. Vinorelbine (Navelbine) as a salvage treatment for advanced breast cancer. Ann Oncol 1994; 5(5): 423-426.

  5. Del Turco MR, Palli D, Cariddi A, et al. Intensive diagnostic follow-up after treatment of primary breast cancer: a randomized trial. JAMA 1994; 271(20): 1593-7.

  6. Feller WF, Holt R, Spear S, et al. Modified radical mastectomy with immediate breast reconstruction. Ann Surg 1986; 52(3): 129-33.

  7. Fisher B, Dignam J, Mamounas EP, et al. Sequential methotrexate and fluorouracil for the treatment of node-negative breast cancer patients with estrogen receptor-negative tumors: eight-year results from National Surgical Adjuvant Breast and Bowel Project (NSABP) B-13 and first report of findings from NSABP B-19 comparing methotrexate and fluorouracil with conventional cyclophosphamide, methotrexate, and fluorouracil. J Clin Oncol 1996; 14(7): 1982-92.

  8. Fisher B, Fisher ER, Redmond C, et al. Tumor nuclear grade, estrogen receptor, and progesterone receptor: their value alone or in combination as indicators of outcome following adjuvant therapy for breast cancer. Breast Can Res Treat 1986; 7(3): 147-160.

  9. Gustafsson A, Tartter PI, Brower ST, et al. Prognosis of patients with bilateral carcinoma of the breast. J Am Coll Surg 1994; 178(2): 111-6.

  10. Halverson KJ, Perez CA, Kuske RR, et al. Survival following locoregional recurrence of breast cancer: univariate and multivariate analysis. International J Radiat Oncol Biol Physics 1992; 23(2): 285-291.

  11. Hang-Fu L, Snyderman RK. State-of-the-art breast reconstruction. Cancer 1991; 68(Suppl 5): 1148-56.

  12. Hughes KS. Cancer and Leukemia Group B: Phase III Randomized Study of Adjuvant Tamoxifen with vs without Radiotherapy Following Lumpectomy for Carcinoma of the Breast No Greater Than 2 cm with Clinically Negative Axillary Nodes in Women Age 70 and Over (Summary Last Modified 05/1999), CLB-9343, clinical trial, closed, 02/26/1999.

  13. Jacobson JA, Danforth DN, Cowan KH, et al. Ten-year results of a comparison of conservation with mastectomy in the treatment of stage I and II breast cancer. NEJM 1995; 332(14): 907-11.

  14. Larson D, Weinstein M, Goldberg I, et al. Edema of the arm as a function of the extent of axillary surgery in patients with stage I-II carcinoma of the breast treated with primary radiotherapy. Int J Radiat Oncol Biol Physics 1986; 12(9): 1575-82.

  15. Love RR, Barden HS, Mazess RB, et al. Effect of tamoxifen on lumbar spine bone mineral density in postmenopausal women after 5 years. Arch Int Med 1994; 154(22): 2585-8.

  16. Moliterni A, Bonadonna G, Valagussa P, et al. Cyclophosphamide, methotrexate, and fluorouracil with and without doxorubicin in the adjuvant treatment of resectable breast cancer with one to three positive axillary nodes. J Clin Oncol 1991; 9(7): 1124-30.

  17. National Cancer Institute: Misconduct suspected in South African study: but door not closed on high-dose chemotherapy for breast cancer. NCI Cancer Trials Resource Page Available at: http/cancertrials. nci.nih.gov/types/breast/treatment/transplant/resutls/saf.html. Accessed 3/2/00.

  18. Norton L, Slamon D, Leyland-Jones B, et al. Overall survival (OS) advantage to simultaneous chemotherapy (CRx) plus the humanized anti-HER2 monoclonal antibody Herceptin (H) in HER2-overexpression (HER2+) metastatic breast cancer (MBC). Procee Am Soc Clin Oncol 1999; 18: 483A, 127a.

  19. Peethambaram PP, Ingle JN, Suman VJ, et al. Randomized trial of diethylstilbestrol vs tamoxifen in postmenopausal women with metastatic breast cancer: an updated analysis. Breast Cancer Res Treatment 1999; 54(2): 117-122.

  20. Rosen PP, Groshen S, Kinne DW. Prognosis in T2N0M0 stage I breast carcinoma: a 20-year follow-up study. J Clin Oncol 1991; 9(9): 1650-1661.

  21. Rutqvist LE, Mattsson A. Cardiac and thromboembolic morbidity among postmenopausal women with early-stage breast cancer in a randomized trial of adjuvant tamoxifen. J Nat Cancer Inst 1993; 85(17): 1398-406.

  22. Storm HH, Andersson M, Boice JD, et al. Adjuvant radiotherapy and risk of contralateral breast cancer. J Nat Cancer Inst 1992; 84(16): 1245-50.

  23. Swedborg I, Wallgren A. The effect of pre-and postmastectomy radiotherapy on the degree of edema, shoulder-joint mobility, and gripping force. Cancer 1981; 47(5): 877-81.

  24. Taghian A, de Vathaire F, Terrier P, et al. Long-term risk of sarcoma following radiation treatment for breast cancer. Int J Radiat Oncol Biol Physics 1991; 21(2): 361-7.

  25. The International Breast Cancer Study Group: Effectiveness of adjuvant chemotherapy in combination with tamoxifen for node-positive postmenopausal breast cancer patients. J Clinic Oncol 1997; 15(4): 1385-1394.

  26. Veronesi U, Banfi A, Salvadori B, et al. Breast conservation is the treatment of choice in small breast cancer: long-term results of a randomized trial. Eur J Can 1990; 26(6): 668-70.

  27. Wazer DE, Schmidt-Ullrich RK, Schmid CH, et al. The value of breast lumpectomy margin assessment as a predictor of residual tumor burden. Int J Radiat Oncol Biol Physics 1997; 38(2): 291-9.

  28. Wolmark N. National Surgical Adjuvant Breast and Bowel Project: Phase III Comparison of Intensive Cyclophosphamide/Doxorubicin (AC) + Tamoxifen vs Conventional Cyclophosphamide/Methotrexate/Fluorouracil CMF) + Tamoxifen Following Complete Resection of Node-Negative, Estrogen Receptor-Negative Adenocarcinoma of the Breast (Summary Last Modified 02/1999), NSABP-B-23, clinical trial, closed, 12/31/1998.

  29. Yeatman TJ, Cantor AB, Smith TJ, et al. Tumor biology of infiltrating lobular carcinoma: implications for management. Ann Surg 1995; 222(4): 549-61.




2020     |     www.medigraphic.com